BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV, Robinson CR, Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313-1316. [PMID: 8385741 DOI: 10.1056/nejm199305063281805] [Cited by in Crossref: 1088] [Cited by in F6Publishing: 294] [Article Influence: 37.5] [Reference Citation Analysis]
Number Citing Articles
1 Kim K, Wu HG, Park SW, Kim CJ, Park CI. Expression of cyclooxygenase (COX)-2 as a prognostic factor in nasopharyngeal cancer. Cancer Res Treat 2004;36:187-91. [PMID: 20396543 DOI: 10.4143/crt.2004.36.3.187] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
2 Shen TY. Discovery of Sulindac, a Reversible Prodrug, as a Second-Generation Indomethacin. In: Merluzzi VJ, Adams J, editors. The Search for Anti-Inflammatory Drugs. Boston: Birkhäuser; 1995. pp. 105-28. [DOI: 10.1007/978-1-4615-9846-6_4] [Cited by in Crossref: 1] [Article Influence: 0.0] [Reference Citation Analysis]
3 Terdiman JP, Johnson LK, Kim YS, Sleisenger MH, Gum JR, Hayes A, Weinberg VK, McQuaid KR. Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Dig Dis Sci. 2009;54:2488-2496. [PMID: 19757048 DOI: 10.1007/s10620-009-0966-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
4 Wang WH, Liu FX, Wang J, Hu FL. Use of non-steroidal anti-inflammatory drug and colorectal polyps: a systematic review and Meta-analysis. Shijie Huaren Xiaohua Zazhi 2008; 16(24): 2724-2733 [DOI: 10.11569/wcjd.v16.i24.2724] [Reference Citation Analysis]
5 Lynch PM. Chemoprevention with special reference to inherited colorectal cancer. Fam Cancer. 2008;7:59-64. [PMID: 17680350 DOI: 10.1007/s10689-007-9158-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
6 Meyskens FL Jr. Therapeutic prevention of colorectal carcinogenesis. J Carcinog 2011;10:13. [PMID: 21712960 DOI: 10.4103/1477-3163.79682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
7 Giardiello FM, Casero RA Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004;126:425-31. [PMID: 14762779 DOI: 10.1053/j.gastro.2003.11.013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
8 Yang W, Bancroft L, Liang J, Zhuang M, Augenlicht LH. p27kip1 in intestinal tumorigenesis and chemoprevention in the mouse. Cancer Res 2005;65:9363-8. [PMID: 16230399 DOI: 10.1158/0008-5472.CAN-05-2113] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ishikawa H, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial. Cancer Med. 2013;2:50-56. [PMID: 24133627 DOI: 10.1002/cam4.46] [Cited by in Crossref: 54] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
10 Tesei A, Ulivi P, Fabbri F, Rosetti M, Leonetti C, Scarsella M, Zupi G, Amadori D, Bolla M, Zoli W. In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines. J Transl Med 2005;3:7. [PMID: 15691389 DOI: 10.1186/1479-5876-3-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
11 Giardiello FM, Offerhaus JA, Tersmette AC, Hylind LM, Krush AJ, Brensinger JD, Booker SV, Hamilton SR. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996;38:578-81. [PMID: 8707091 DOI: 10.1136/gut.38.4.578] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 2.2] [Reference Citation Analysis]
12 Smeenk HG, Tran TC, Erdmann J, van Eijck CH, Jeekel J. Survival after surgical management of pancreatic adenocarcinoma: does curative and radical surgery truly exist? Langenbecks Arch Surg 2005;390:94-103. [PMID: 15578211 DOI: 10.1007/s00423-004-0476-9] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 3.7] [Reference Citation Analysis]
13 Chariyalertsak S, Sirikulchayanonta V, Mayer D, Kopp-Schneider A, Fürstenberger G, Marks F, Müller-Decker K. Aberrant cyclooxygenase isozyme expression in human intrahepatic cholangiocarcinoma. Gut. 2001;48:80-86. [PMID: 11115827 DOI: 10.1136/gut.48.1.80] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
14 Davis-Yadley AH, Lipka S, Shen H, Shah H, Swarup S, Barnowsky A, Silpe J, Mosdale J, Pan Q, Fridlyand S, Sreeharshan S, Abraham A, Viswanathan P, Krishnamachari B. Ethnic disparities in the risk of colorectal adenomas associated with aspirin and statin use: a retrospective multiethnic study. J Gastrointest Oncol 2014;5:112-8. [PMID: 24772339 DOI: 10.3978/j.issn.2078-6891.2014.010] [Reference Citation Analysis]
15 Boon EM, Keller JJ, Wormhoudt TA, Giardiello FM, Offerhaus GJ, van der Neut R, Pals ST. Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer 2004;90:224-9. [PMID: 14710233 DOI: 10.1038/sj.bjc.6601505] [Cited by in Crossref: 140] [Cited by in F6Publishing: 132] [Article Influence: 7.8] [Reference Citation Analysis]
16 Femia AP, Soares PV, Luceri C, Lodovici M, Giannini A, Caderni G. Sulindac, 3,3'-diindolylmethane and curcumin reduce carcinogenesis in the Pirc rat, an Apc-driven model of colon carcinogenesis. BMC Cancer 2015;15:611. [PMID: 26335331 DOI: 10.1186/s12885-015-1627-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
17 Verschoyle RD, Greaves P, Cai H, Edwards RE, Steward WP, Gescher AJ. Evaluation of the cancer chemopreventive efficacy of rice bran in genetic mouse models of breast, prostate and intestinal carcinogenesis. Br J Cancer 2007;96:248-54. [PMID: 17211473 DOI: 10.1038/sj.bjc.6603539] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
18 Piazza GA, Keeton AB, Tinsley HN, Gary BD, Whitt JD, Mathew B, Thaiparambil J, Coward L, Gorman G, Li Y. A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. Cancer Prev Res (Phila). 2009;2:572-580. [PMID: 19470791 DOI: 10.1158/1940-6207.CAPR-09-0001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
19 Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB, Piazza GA. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 2010;3:1303-13. [PMID: 20876730 DOI: 10.1158/1940-6207.CAPR-10-0030] [Cited by in Crossref: 53] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
20 Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, Stefanick ML, Taylor V, Garland C, Frank G, Lane D. Conjugated equine estrogens and colorectal cancer incidence and survival: the Women’s Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008;17:2609-2618. [PMID: 18829444 DOI: 10.1158/1055-9965.epi-08-0385] [Cited by in Crossref: 63] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
21 Li X, Gao L, Cui Q, Gary BD, Dyess DL, Taylor W, Shevde LA, Samant RS, Dean-Colomb W, Piazza GA, Xi Y. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene 2012;31:4979-86. [PMID: 22286762 DOI: 10.1038/onc.2011.655] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
22 Liggett JL, Zhang X, Eling TE, Baek SJ. Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets. Cancer Lett 2014;346:217-24. [PMID: 24486220 DOI: 10.1016/j.canlet.2014.01.021] [Cited by in Crossref: 66] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
23 Zhi YH, Liu RS, Song MM, Tian Y, Long J, Tu W, Guo RX. Cyclooxygenase-2 promotes angiogenesis by increasing vascular endothelial growth factor and predicts prognosis in gallbladder carcinoma. World J Gastroenterol 2005; 11(24): 3724-3728 [PMID: 15968728 DOI: 10.3748/wjg.v11.i24.3724] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 37] [Article Influence: 2.3] [Reference Citation Analysis]
24 Herzig D, Hardiman K, Weiser M, You N, Paquette I, Feingold DL, Steele SR. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes. Dis Colon Rectum. 2017;60:881-894. [PMID: 28796726 DOI: 10.1097/dcr.0000000000000912] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
25 Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40. [PMID: 9096394 DOI: 10.1073/pnas.94.7.3336] [Cited by in Crossref: 963] [Cited by in F6Publishing: 911] [Article Influence: 38.5] [Reference Citation Analysis]
26 Kandil HM, Argenzio RA, Sartor RB. Low endogenous prostaglandin E2 predisposes to relapsing inflammation in experimental rat enterocolitis. Dig Dis Sci 2000;45:2091-9. [PMID: 11215721 DOI: 10.1023/a:1026675005554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Piazza GA, Keeton AB, Tinsley HN, Whitt JD, Gary BD, Mathew B, Singh R, Grizzle WE, Reynolds RC. NSAIDs: Old Drugs Reveal New Anticancer Targets. Pharmaceuticals (Basel) 2010;3:1652-67. [PMID: 27713322 DOI: 10.3390/ph3051652] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
28 Laukaitis CM, Erdman SH, Gerner EW. Chemoprevention in patients with genetic risk of colorectal cancers. Colorectal Cancer 2012;1:225-40. [PMID: 25221625 DOI: 10.2217/crc.12.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Hoppe-Seyler F, Butz K. Tumor suppressor genes in molecular medicine. Clin Investig. 1994;72:619-630. [PMID: 7819720 DOI: 10.1007/bf00227456] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
30 Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut. 2001;49:443-453. [PMID: 11511570 DOI: 10.1136/gut.49.3.443] [Cited by in Crossref: 156] [Cited by in F6Publishing: 149] [Article Influence: 7.4] [Reference Citation Analysis]
31 Kahn M. Can we safely target the WNT pathway? Nat Rev Drug Discov. 2014;13:513-532. [PMID: 24981364 DOI: 10.1038/nrd4233] [Cited by in Crossref: 595] [Cited by in F6Publishing: 567] [Article Influence: 74.4] [Reference Citation Analysis]
32 Ayiomamitis GD, Notas G, Vasilakaki T, Tsavari A, Vederaki S, Theodosopoulos T, Kouroumalis E, Zaravinos A. Understanding the Interplay between COX-2 and hTERT in Colorectal Cancer Using a Multi-Omics Analysis. Cancers (Basel) 2019;11:E1536. [PMID: 31614548 DOI: 10.3390/cancers11101536] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
33 Kandil HM, Argenzio RA, Sartor RB. Low endogenous prostaglandin E2 predisposes to relapsing inflammation in experimental rat enterocolitis. Dig Dis Sci 1999;44:2110-8. [PMID: 10548365 DOI: 10.1023/a:1026694907238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Kashfi K, Chattopadhyay M, Kodela R. NOSH-sulindac (AVT-18A) is a novel nitric oxide- and hydrogen sulfide-releasing hybrid that is gastrointestinal safe and has potent anti-inflammatory, analgesic, antipyretic, anti-platelet, and anti-cancer properties. Redox Biol 2015;6:287-96. [PMID: 26298203 DOI: 10.1016/j.redox.2015.08.012] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
35 Wahab PJ, Peters WH, Roelofs HM, Jansen JB. Glutathione S-transferases in small intestinal mucosa of patients with coeliac disease. Jpn J Cancer Res 2001;92:279-84. [PMID: 11267937 DOI: 10.1111/j.1349-7006.2001.tb01092.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
36 Nolfo F, Rametta S, Marventano S, Grosso G, Mistretta A, Drago F, Gangi S, Basile F, Biondi A. Pharmacological and dietary prevention for colorectal cancer. BMC Surg. 2013;13 Suppl 2:S16. [PMID: 24267792 DOI: 10.1186/1471-2482-13-s2-s16] [Cited by in Crossref: 18] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
37 Gold KA, Kim ES, Lee JJ, Wistuba II, Farhangfar CJ, Hong WK. The BATTLE to personalize lung cancer prevention through reverse migration. Cancer Prev Res (Phila) 2011;4:962-72. [PMID: 21733820 DOI: 10.1158/1940-6207.CAPR-11-0232] [Cited by in Crossref: 38] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
38 Greenwell JC, Torres-Gonzalez E, Ritzenthaler JD, Roman J. Interplay between aging, lung inflammation/remodeling, and fibronectin EDA in lung cancer progression. Cancer Biol Ther 2020;21:1109-18. [PMID: 33222614 DOI: 10.1080/15384047.2020.1831372] [Reference Citation Analysis]
39 Zimmermann KC, Waterhouse NJ, Goldstein JC, Schuler M, Green DR. Aspirin induces apoptosis through release of cytochrome c from mitochondria. Neoplasia. 2000;2:505-513. [PMID: 11228543 DOI: 10.1038/sj.neo.7900120] [Cited by in Crossref: 70] [Cited by in F6Publishing: 62] [Article Influence: 3.5] [Reference Citation Analysis]
40 Lott PC, Carvajal-Carmona LG. Resolving gastric cancer aetiology: an update in genetic predisposition. Lancet Gastroenterol Hepatol. 2018;3:874-883. [PMID: 30507471 DOI: 10.1016/s2468-1253(18)30237-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
41 Zhao H, Yi B, Liang Z, Phillips C, Lin HY, Riker AI, Xi Y. Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer. Genes Dis 2021;8:320-30. [PMID: 33997179 DOI: 10.1016/j.gendis.2020.11.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Cancer and inflammation: promise for biologic therapy. J Immunother 2010;33:335-51. [PMID: 20386472 DOI: 10.1097/CJI.0b013e3181d32e74] [Cited by in Crossref: 212] [Cited by in F6Publishing: 116] [Article Influence: 17.7] [Reference Citation Analysis]
43 Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106:1340-1350. [PMID: 21407185 DOI: 10.1038/ajg.2011.38] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 9.1] [Reference Citation Analysis]
44 Samadder NJ, Neklason DW, Boucher KM, Byrne KR, Kanth P, Samowitz W, Jones D, Tavtigian SV, Done MW, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Davis R, Topham MK, Lynch P, Strait E, McKinnon W, Burt RW, Kuwada SK. Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial. JAMA 2016;315:1266-75. [PMID: 27002448 DOI: 10.1001/jama.2016.2522] [Cited by in Crossref: 70] [Cited by in F6Publishing: 54] [Article Influence: 11.7] [Reference Citation Analysis]
45 Ma R, Yi B, Piazza GA, Xi Y. Mechanistic Role of MicroRNA in Cancer Chemoprevention by Nonsteroidal Anti-inflammatory Drugs. Curr Pharmacol Rep 2015;1:154-60. [PMID: 26213681 DOI: 10.1007/s40495-014-0011-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
46 Zhu GH, Wong BC, Eggo MC, Ching CK, Yuen ST, Chan EY, Lai KC, Lam SK. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc. Br J Cancer. 1999;79:393-400. [PMID: 10027304 DOI: 10.1038/sj.bjc.6690062] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 1.3] [Reference Citation Analysis]
47 Hyer W, Fell JM. Screening for familial adenomatous polyposis. Arch Dis Child 2001;84:377-80. [PMID: 11316674 DOI: 10.1136/adc.84.5.377] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
48 Shussman N, Wexner SD. Colorectal polyps and polyposis syndromes. Gastroenterol Rep (Oxf). 2014;2:1-15. [PMID: 24760231 DOI: 10.1093/gastro/got041] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
49 Lamont EB, Dias LE, Lauderdale DS. NSAIDs and colorectal cancer risk: do administrative data support a chemopreventive effect? J Gen Intern Med 2007;22:1166-71. [PMID: 17577606 DOI: 10.1007/s11606-007-0256-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
50 Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis. 2003;18:392-400. [PMID: 12904996 DOI: 10.1007/s00384-002-0476-6] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
51 Chen L, He Y, Huang H, Liao H, Wei W. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Med Oncol 2008;25:161-71. [PMID: 18172786 DOI: 10.1007/s12032-007-9015-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
52 Reuter BK, Zhang XJ, Miller MJ. Therapeutic utility of aspirin in the ApcMin/+ murine model of colon carcinogenesis. BMC Cancer 2002;2:19. [PMID: 12171603 DOI: 10.1186/1471-2407-2-19] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
53 Vanoli A, Grillo F, Furlan D, Arpa G, Grami O, Guerini C, Riboni R, Mastracci L, Di Sabatino A. Small Bowel Epithelial Precursor Lesions: A Focus on Molecular Alterations. Int J Mol Sci 2021;22:4388. [PMID: 33922305 DOI: 10.3390/ijms22094388] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Chia WK, Ali R, Toh HC. Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. Nat Rev Clin Oncol. 2012;9:561-570. [PMID: 22910681 DOI: 10.1038/nrclinonc.2012.137] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 7.3] [Reference Citation Analysis]
55 Tsioulias GJ, Go MF, Rigas B. NSAIDs and Colorectal Cancer Control: Promise and Challenges. Curr Pharmacol Rep 2015;1:295-301. [PMID: 26688785 DOI: 10.1007/s40495-015-0042-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
56 Novellasdemunt L, Antas P, Li VS. Targeting Wnt signaling in colorectal cancer. A Review in the Theme: Cell Signaling: Proteins, Pathways and Mechanisms. Am J Physiol Cell Physiol. 2015;309:C511-C521. [PMID: 26289750 DOI: 10.1152/ajpcell.00117.2015] [Cited by in Crossref: 182] [Cited by in F6Publishing: 172] [Article Influence: 26.0] [Reference Citation Analysis]
57 Cruz-Correa M, Gonzalez-Pons MDM. Reassessing colectomy in young patients with familial adenomatous polyposis. Gastrointest Endosc 2018;88:734-6. [PMID: 30217246 DOI: 10.1016/j.gie.2018.07.001] [Reference Citation Analysis]
58 Thompson PA, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu CH, Chow SH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez EM, Alberts DS, Lance P. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. J Natl Cancer Inst. 2016;108. [PMID: 27530656 DOI: 10.1093/jnci/djw151] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
59 Yoshimi N, Kawabata K, Hara A, Matsunaga K, Yamada Y, Mori H. Inhibitory effect of NS-398, a selective cyclooxygenase-2 inhibitor, on azoxymethane-induced aberrant crypt foci in colon carcinogenesis of F344 rats. Jpn J Cancer Res. 1997;88:1044-1051. [PMID: 9439679 DOI: 10.1111/j.1349-7006.1997.tb00328.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.4] [Reference Citation Analysis]
60 Hall MJ. Updates in chemoprevention research for hereditary gastrointestinal and polyposis syndromes. Curr Treat Options Gastroenterol 2021;19:30-46. [PMID: 34211259 DOI: 10.1007/s11938-020-00306-x] [Reference Citation Analysis]
61 Takahashi M, Ota S, Hata Y, Mikami Y, Azuma N, Nakamura T, Terano A, Omata M. Hepatocyte growth factor as a key to modulate anti-ulcer action of prostaglandins in stomach. J Clin Invest 1996;98:2604-11. [PMID: 8958224 DOI: 10.1172/JCI119080] [Cited by in Crossref: 64] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
62 Bolger JK, Tian W, Wolter WR, Cho W, Suckow MA, Miller MJ. Synthesis and evaluation of 5-lipoxygenase translocation inhibitors from acylnitroso hetero-Diels-Alder cycloadducts. Org Biomol Chem 2011;9:2999-3010. [PMID: 21365098 DOI: 10.1039/c0ob00714e] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
63 Murgic J, Kirac I, Soldic Z, Tomas D, Zovak M, Bolanca A, Plawski A, Banasiewicz Y, Kusic Z. Familial adenomatous polyposis in three generations of a single family: a case study. Case Rep Oncol 2014;7:349-56. [PMID: 24987355 DOI: 10.1159/000363221] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
64 Goodman GE. Assessing toxicity in cancer chemoprevention trials: the other side of the coin. Cancer Prev Res (Phila) 2008;1:499-502. [PMID: 19138998 DOI: 10.1158/1940-6207.CAPR-08-0186] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
65 Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ; Cancer Prevention Network. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiol Biomarkers Prev 2008;17:674-9. [PMID: 18349286 DOI: 10.1158/1055-9965.EPI-07-2510] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
66 Ye X, Wu H, Sheng L, Liu YX, Ye F, Wang M, Zhou H, Su Y, Zhang XK. Oncogenic potential of truncated RXRα during colitis-associated colorectal tumorigenesis by promoting IL-6-STAT3 signaling. Nat Commun 2019;10:1463. [PMID: 30931933 DOI: 10.1038/s41467-019-09375-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
67 Omura N, Griffith M, Vincent A, Li A, Hong SM, Walter K, Borges M, Goggins M. Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins. Mol Cancer Res 2010;8:821-32. [PMID: 20530583 DOI: 10.1158/1541-7786.MCR-09-0336] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
68 Stolley PD, Zahm SH. Nonhormonal drugs and cancer. Environ Health Perspect 1995;103 Suppl 8:191-6. [PMID: 8741782 DOI: 10.1289/ehp.95103s8191] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
69 Reis ED, Roque M, Dansky H, Fallon JT, Badimon JJ, Cordon-Cardo C, Shiff SJ, Fisher EA. Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice. Proc Natl Acad Sci USA. 2000;97:12764-12769. [PMID: 11027305 DOI: 10.1073/pnas.210394497] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
70 Rigas B, Tsioulias GJ. The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism. J Pharmacol Exp Ther 2015;353:2-8. [PMID: 25589413 DOI: 10.1124/jpet.114.220806] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.9] [Reference Citation Analysis]
71 Meyskens FL, Mukhtar H, Rock CL, Cuzick J, Kensler TW, Yang CS, Ramsey SD, Lippman SM, Alberts DS. Cancer Prevention: Obstacles, Challenges and the Road Ahead. J Natl Cancer Inst. 2015;108. [PMID: 26547931 DOI: 10.1093/jnci/djv309] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 7.0] [Reference Citation Analysis]
72 Bisgin A, Kargi A, Yalcin AD, Aydin C, Ekinci D, Savas B, Sanlioglu S. Increased serum sTRAIL levels were correlated with survival in bevacizumab-treated metastatic colon cancer. BMC Cancer 2012;12:58. [PMID: 22313795 DOI: 10.1186/1471-2407-12-58] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
73 Peleg II, Lubin MF, Cotsonis GA, Clark WS, Wilcox CM. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis Sci 1996;41:1319-26. [PMID: 8689906 DOI: 10.1007/BF02088554] [Cited by in Crossref: 63] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
74 Bostick RM. Effects of supplemental vitamin D and calcium on normal colon tissue and circulating biomarkers of risk for colorectal neoplasms. J Steroid Biochem Mol Biol. 2015;148:86-95. [PMID: 25597952 DOI: 10.1016/j.jsbmb.2015.01.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
75 Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997;100:1325-9. [PMID: 9294096 DOI: 10.1172/JCI119651] [Cited by in Crossref: 169] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
76 Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, Chaussade S, Baron JA. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101:256-266. [PMID: 19211452 DOI: 10.1093/jnci/djn485] [Cited by in Crossref: 341] [Cited by in F6Publishing: 295] [Article Influence: 26.2] [Reference Citation Analysis]
77 Hisamuddin IM, Yang VW. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives. Pharmacogenomics 2007;8:635-43. [PMID: 17559352 DOI: 10.2217/14622416.8.6.635] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
78 Katona BW, Weiss JM. Chemoprevention of Colorectal Cancer. Gastroenterology 2020;158:368-88. [PMID: 31563626 DOI: 10.1053/j.gastro.2019.06.047] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
79 Sun WH, Yu Q, Shen H, Ou XL, Cao DZ, Yu T, Qian C, Zhu F, Sun YL, Fu XL, Su H. Roles of Helicobacter pylori infection and cyclooxygenase-2 expression in gastric carcinogenesis. World J Gastroenterol 2004; 10(19): 2809-2813 [PMID: 15334675 DOI: 10.3748/wjg.v10.i19.2809] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.1] [Reference Citation Analysis]
80 Zhang Y, Zhang J, Wang L, Quealy E, Gary BD, Reynolds RC, Piazza GA, Lü J. A novel sulindac derivative lacking cyclooxygenase-inhibitory activities suppresses carcinogenesis in the transgenic adenocarcinoma of mouse prostate model. Cancer Prev Res (Phila) 2010;3:885-95. [PMID: 20587701 DOI: 10.1158/1940-6207.CAPR-09-0273] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
81 Meyskens FL, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, Kelloff G, Lawson MJ, Kidao J, McCracken J. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008;1:32-38. [PMID: 18841250 DOI: 10.1158/1940-6207.capr-08-0042] [Cited by in Crossref: 345] [Cited by in F6Publishing: 228] [Article Influence: 26.5] [Reference Citation Analysis]
82 Koshiba T, Hosotani R, Miyamoto Y, Wada M, Lee JU, Fujimoto K, Tsuji S, Nakajima S, Doi R, Imamura M. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors. Int J Pancreatol. 1999;26:69-76. [PMID: 10597402 DOI: 10.1007/bf02781733] [Cited by in Crossref: 49] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
83 Oshima H, Oshima M. The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol. 2013;35:139-150. [PMID: 23053397 DOI: 10.1007/s00281- 012-0353-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Altobelli E, Angeletti PM, Latella G. Role of Urinary Biomarkers in the Diagnosis of Adenoma and Colorectal Cancer: A Systematic Review and Meta-Analysis. J Cancer. 2016;7:1984-2004. [PMID: 27877214 DOI: 10.7150/jca.16244] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
85 Regoes RR. Population genetics meets cancer genomics. Proc Natl Acad Sci U S A 2010;107:18241-2. [PMID: 20935251 DOI: 10.1073/pnas.1013177107] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
86 Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 138: 2029-2043. e10. [PMID: 20420944 DOI: 10.1053/j.gastro.2010.01.057] [Cited by in Crossref: 356] [Cited by in F6Publishing: 322] [Article Influence: 29.7] [Reference Citation Analysis]
87 Entezari AA, Snook AE, Waldman SA. Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. Expert Opin Ther Targets 2021;25:335-46. [PMID: 34056991 DOI: 10.1080/14728222.2021.1937124] [Reference Citation Analysis]
88 Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, Logan RF, Rothwell PM, Schrör K, Baron JA. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila). 2012;5:164-178. [PMID: 22084361 DOI: 10.1158/1940-6207.capr-11-0391] [Cited by in Crossref: 181] [Cited by in F6Publishing: 98] [Article Influence: 16.5] [Reference Citation Analysis]
89 Lee YS, Choi D, Kim NY, Yang S, Jung E, Hong M, Yang D, Lenz HJ, Hong YK. CXCR2 inhibition enhances sulindac-mediated suppression of colon cancer development. Int J Cancer. 2014;135:232-237. [PMID: 24338666 DOI: 10.1002/ijc.28668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
90 Piazza GA. Validation of PDE5 as a Chemoprevention Target. Cancer Prev Res (Phila) 2017;10:373-6. [PMID: 28600399 DOI: 10.1158/1940-6207.CAPR-17-0136] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
91 Sharma RA, Gescher AJ, O'Byrne KJ, Steward WP. Familiar drugs may prevent cancer. Postgrad Med J 2001;77:492-7. [PMID: 11470927 DOI: 10.1136/pmj.77.910.492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
92 DuBois RN, Awad J, Morrow J, Roberts LJ 2nd, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-alpha and phorbol ester. J Clin Invest. 1994;93:493-498. [PMID: 8113389 DOI: 10.1172/jci116998] [Cited by in Crossref: 255] [Cited by in F6Publishing: 62] [Article Influence: 9.1] [Reference Citation Analysis]
93 Gold KA, Kim ES, Wistuba II, Hong WK. Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem 2013;329:221-40. [PMID: 22752582 DOI: 10.1007/128_2012_338] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
94 Li X, Pathi SS, Safe S. Sulindac sulfide inhibits colon cancer cell growth and downregulates specificity protein transcription factors. BMC Cancer 2015;15:974. [PMID: 26673922 DOI: 10.1186/s12885-015-1956-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
95 Chokshi RJ, Abdel-Misih S, Bloomston M. Surgical management of colorectal cancer: A review of the literature. Indian J Surg 2009;71:350-5. [PMID: 23133190 DOI: 10.1007/s12262-009-0093-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
96 Delker DA, Wood AC, Snow AK, Samadder NJ, Samowitz WS, Affolter KE, Boucher KM, Pappas LM, Stijleman IJ, Kanth P, Byrne KR, Burt RW, Bernard PS, Neklason DW. Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia. Cancer Prev Res (Phila) 2018;11:4-15. [PMID: 29109117 DOI: 10.1158/1940-6207.CAPR-17-0130] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
97 Click RE. Anticancer activity and chemoprevention of xenobiotic organosulfurs in preclinical model systems. Oncol Discov 2013;1. [PMID: 25383193 DOI: 10.7243/2052-6199-1-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
98 Waller A, Findeis S, Lee MJ. Familial Adenomatous Polyposis. J Pediatr Genet 2016;5:78-83. [PMID: 27617147 DOI: 10.1055/s-0036-1579760] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
99 Williams CS, Sheng H, Brockman JA, Armandla R, Shao J, Washington MK, Elkahloun AG, DuBois RN. A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia 2001;3:428-36. [PMID: 11687954 DOI: 10.1038/sj.neo.7900177] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.1] [Reference Citation Analysis]
100 Roser C, Tóth C, Renner M, Herpel E, Schirmacher P. Expression of apoptosis repressor with caspase recruitment domain (ARC) in familial adenomatous polyposis (FAP) adenomas and its correlation with DNA mismatch repair proteins, p53, Bcl-2, COX-2 and beta-catenin. Cell Commun Signal 2021;19:15. [PMID: 33579312 DOI: 10.1186/s12964-020-00702-x] [Reference Citation Analysis]
101 Lai KKY, Kahn M. Pharmacologically Targeting the WNT/β-Catenin Signaling Cascade: Avoiding the Sword of Damocles. Handb Exp Pharmacol 2021;269:383-422. [PMID: 34463849 DOI: 10.1007/164_2021_523] [Reference Citation Analysis]
102 Schnitzler M, Dwight T, Robinson BG. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study. Gut 1996;38:707-13. [PMID: 8707116 DOI: 10.1136/gut.38.5.707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
103 Martinez ME, O’Brien TG, Fultz KE, Babbar N, Yerushalmi H, Qu N, Guo Y, Boorman D, Einspahr J, Alberts DS. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA. 2003;100:7859-7864. [PMID: 12810952 DOI: 10.1073/pnas.1332465100] [Cited by in Crossref: 142] [Cited by in F6Publishing: 116] [Article Influence: 7.5] [Reference Citation Analysis]
104 Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Feng Z, Bronner MP. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 2000;157:737-45. [PMID: 10980113 DOI: 10.1016/S0002-9440(10)64587-7] [Cited by in Crossref: 114] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
105 Liu JP, Zhu ZH. Correlation of COX-2 expression and clinicopathological features of colorectal cancer. Shijie Huaren Xiaohua Zazhi 2003; 11(3): 306-309 [DOI: 10.11569/wcjd.v11.i3.306] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
106 Keller JJ, Offerhaus GJ, Polak M, Goodman SN, Zahurak ML, Hylind LM, Hamilton SR, Giardiello FM. Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. Gut. 1999;45:822-828. [PMID: 10562579 DOI: 10.1136/gut.45.6.822] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 2.0] [Reference Citation Analysis]
107 Manzano A, Pérez-Segura P. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? ScientificWorldJournal 2012;2012:327341. [PMID: 22649288 DOI: 10.1100/2012/327341] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
108 Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA. 2000;97:11280-11285. [PMID: 11005842 DOI: 10.1073/pnas.200367597] [Cited by in Crossref: 285] [Cited by in F6Publishing: 279] [Article Influence: 13.0] [Reference Citation Analysis]
109 Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA. 2010;107:18545-18550. [PMID: 20876136 DOI: 10.1073/pnas.1010978107] [Cited by in Crossref: 531] [Cited by in F6Publishing: 424] [Article Influence: 44.3] [Reference Citation Analysis]
110 Charalambous MP, Lightfoot T, Speirs V, Horgan K, Gooderham NJ. Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer. 2009;101:106-115. [PMID: 19513071 DOI: 10.1038/sj.bjc.6605120] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 4.2] [Reference Citation Analysis]
111 Gurpinar E, Grizzle WE, Piazza GA. NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res 2014;20:1104-13. [PMID: 24311630 DOI: 10.1158/1078-0432.CCR-13-1573] [Cited by in Crossref: 122] [Cited by in F6Publishing: 69] [Article Influence: 13.6] [Reference Citation Analysis]
112 Yun C, Dashwood WM, Kwong LN, Gao S, Yin T, Ling Q, Singh R, Dashwood RH, Hu M. Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. J Pharm Biomed Anal 2018;148:42-50. [PMID: 28957718 DOI: 10.1016/j.jpba.2017.07.025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
113 Fischer JM, Schepers AG, Clevers H, Shibata D, Liskay RM. Occult progression by Apc-deficient intestinal crypts as a target for chemoprevention. Carcinogenesis 2014;35:237-46. [PMID: 23996931 DOI: 10.1093/carcin/bgt296] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
114 Lew JI, Guo Y, Kim RK, Vargish L, Michelassi F, Arenas RB. Reduction of intestinal neoplasia with adenomatous polyposis coli gene replacement and COX-2 inhibition is additive. J Gastrointest. Surg. 2002;6:563-568. [PMID: 12127122 DOI: 10.1016/s1091-255x(01)00042-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
115 Kidambi TD, Kohli DR, Samadder NJ, Singh A. Hereditary Polyposis Syndromes. Curr Treat Options Gastroenterol 2019;17:650-65. [PMID: 31705372 DOI: 10.1007/s11938-019-00251-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
116 Brenner DE, Gescher AJ. Cancer chemoprevention: lessons learned and future directions. Br J Cancer 2005;93:735-9. [PMID: 16160697 DOI: 10.1038/sj.bjc.6602765] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
117 Bundred NJ, Barnes NL. Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer 2005;93 Suppl 1:S10-5. [PMID: 16100520 DOI: 10.1038/sj.bjc.6602690] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
118 Frahm S, Kurtz A, Kluwe L, Farassati F, Friedrich RE, Mautner VF. Sulindac derivatives inhibit cell growth and induce apoptosis in primary cells from malignant peripheral nerve sheath tumors of NF1-patients. Cancer Cell Int 2004;4:4. [PMID: 15147581 DOI: 10.1186/1475-2867-4-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
119 Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67. [PMID: 17326708 DOI: 10.1371/journal.pmed.0040067] [Cited by in Crossref: 190] [Cited by in F6Publishing: 168] [Article Influence: 12.7] [Reference Citation Analysis]
120 Cattaneo MG, Pola S, Dehò V, Sanguini AM, Vicentini LM. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. Br J Pharmacol. 2003;138:377-385. [PMID: 12540529 DOI: 10.1038/sj.bjp.0705051] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
121 Björk J. Strategies for colon cancer prevention. EPMA J 2010;1:513-21. [PMID: 23199093 DOI: 10.1007/s13167-010-0047-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
122 Gash KJ, Chambers AC, Cotton DE, Williams AC, Thomas MG. Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy. Br J Cancer 2017;117:210-9. [PMID: 28641310 DOI: 10.1038/bjc.2017.175] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
123 Williams CS, Goldman AP, Sheng H, Morrow JD, DuBois RN. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia. 1999;1:170-176. [PMID: 10933052 DOI: 10.1038/sj.neo.7900024] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 1.5] [Reference Citation Analysis]
124 Hisamuddin IM, Wehbi MA, Yang VW. Pharmacogenetics and diseases of the colon. Curr Opin Gastroenterol 2007;23:60-6. [PMID: 17133087 DOI: 10.1097/MOG.0b013e32801145c2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
125 Fuentes NR, Kim E, Fan YY, Chapkin RS. Omega-3 fatty acids, membrane remodeling and cancer prevention. Mol Aspects Med 2018;64:79-91. [PMID: 29627343 DOI: 10.1016/j.mam.2018.04.001] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
126 Vasen HF, van Duijvendijk P, Buskens E, Bülow C, Björk J, Järvinen HJ, Bülow S. Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients. Gut. 2001;49:231-235. [PMID: 11454800 DOI: 10.1136/gut.49.2.231] [Cited by in Crossref: 54] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
127 Inaba T, Sano H, Kawahito Y, Hla T, Akita K, Toda M, Yamashina I, Inoue M, Nakada H. Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells. Proc Natl Acad Sci U S A 2003;100:2736-41. [PMID: 12598658 DOI: 10.1073/pnas.0435410100] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 2.6] [Reference Citation Analysis]
128 Mathew B, Hobrath JV, Lu W, Li Y, Reynolds RC. Synthesis and preliminary assessment of the anticancer and Wnt/β-catenin inhibitory activity of small amide libraries of fenamates and profens. Med Chem Res 2017;26:3038-45. [PMID: 29104411 DOI: 10.1007/s00044-017-2001-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
129 Turano M, Cammarota F, Duraturo F, Izzo P, De Rosa M. A Potential Role of IL-6/IL-6R in the Development and Management of Colon Cancer. Membranes (Basel) 2021;11:312. [PMID: 33923292 DOI: 10.3390/membranes11050312] [Reference Citation Analysis]
130 Gerner EW, Bruckheimer E, Cohen A. Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer. J Biol Chem. 2018;293:18770-18778. [PMID: 30355737 DOI: 10.1074/jbc.tm118.003343] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
131 Fajardo AM, Piazza GA. Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemoprevention. Am J Physiol Gastrointest Liver Physiol 2015;309:G59-70. [PMID: 26021807 DOI: 10.1152/ajpgi.00101.2014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 5.4] [Reference Citation Analysis]
132 Bülow S, Berk T, Neale K. The history of familial adenomatous polyposis. Fam Cancer 2006;5:213-20. [PMID: 16998666 DOI: 10.1007/s10689-005-5854-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
133 Ait Ouakrim D, Dashti SG, Chau R, Buchanan DD, Clendenning M, Rosty C, Winship IM, Young JP, Giles GG, Leggett B, Macrae FA, Ahnen DJ, Casey G, Gallinger S, Haile RW, Le Marchand L, Thibodeau SN, Lindor NM, Newcomb PA, Potter JD, Baron JA, Hopper JL, Jenkins MA, Win AK. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst 2015;107:djv170. [PMID: 26109217 DOI: 10.1093/jnci/djv170] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 8.3] [Reference Citation Analysis]
134 Oshima H, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. J Gastroenterol. 2012;47:97-106. [PMID: 22218775 DOI: 10.1007/s00535-011-0523-6] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 7.2] [Reference Citation Analysis]
135 Hara A, Yoshimi N, Niwa M, Ino N, Mori H. Apoptosis induced by NS-398, a selective cyclooxygenase-2 inhibitor, in human colorectal cancer cell lines. Jpn J Cancer Res. 1997;88:600-604. [PMID: 9263538 DOI: 10.1111/j.1349-7006.1997.tb00424.x] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 2.9] [Reference Citation Analysis]
136 Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol. 2000;156:1821-1825. [PMID: 10854204 DOI: 10.1016/s0002-9440(10)65054-7] [Cited by in Crossref: 252] [Cited by in F6Publishing: 105] [Article Influence: 11.5] [Reference Citation Analysis]
137 Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, Grizzle WE, Piazza GA. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. Cancer Prev Res (Phila) 2012;5:822-33. [PMID: 22556201 DOI: 10.1158/1940-6207.CAPR-11-0559] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
138 Kohno H, Suzuki R, Sugie S, Tanaka T. Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005;5:46. [PMID: 15892897 DOI: 10.1186/1471-2407-5-46] [Cited by in Crossref: 89] [Cited by in F6Publishing: 88] [Article Influence: 5.2] [Reference Citation Analysis]
139 Reimers MS, Engels CC, Kuppen PJ, van de Velde CJ, Liefers GJ. How does genome sequencing impact surgery? Nat Rev Clin Oncol 2014;11:610-8. [PMID: 24958181 DOI: 10.1038/nrclinonc.2014.101] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
140 Bi X, Pohl N, Dong H, Yang W. Selenium and sulindac are synergistic to inhibit intestinal tumorigenesis in Apc/p21 mice. J Hematol Oncol 2013;6:8. [PMID: 23327547 DOI: 10.1186/1756-8722-6-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
141 Gala M, Sun R, Yang VW. Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways. Cancer Lett 2002;175:89-94. [PMID: 11734340 DOI: 10.1016/s0304-3835(01)00716-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
142 Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA. 1997;94:2869-2873. [PMID: 9096313 DOI: 10.1073/pnas.94.7.2869] [Cited by in Crossref: 201] [Cited by in F6Publishing: 194] [Article Influence: 8.0] [Reference Citation Analysis]
143 Tinsley HN, Piazza GA. Novel Therapeutics: NSAIDs, Derivatives, and Phosphodiesterases. Curr Colorectal Cancer Rep 2012;8:325-30. [PMID: 23459242 DOI: 10.1007/s11888-012-0142-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
144 Goodman GE. Lung cancer. 1: prevention of lung cancer. Thorax 2002;57:994-9. [PMID: 12403886 DOI: 10.1136/thorax.57.11.994] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
145 Ishikawa H, Nakamura T, Kawano A, Gondo N, Sakai T. Chemoprevention of colorectal cancer in Japan: a brief introduction to current clinical trials. J Gastroenterol. 2009;44 Suppl 19:77-81. [PMID: 19148798 DOI: 10.1007/s00535-008-2286-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
146 Valle L, Vilar E, Tavtigian SV, Stoffel EM. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine. J Pathol 2019;247:574-88. [PMID: 30584801 DOI: 10.1002/path.5229] [Cited by in Crossref: 49] [Cited by in F6Publishing: 39] [Article Influence: 16.3] [Reference Citation Analysis]
147 Kim KY, Jeon SW, Park JG, Yu CH, Jang SY, Lee JK, Hwang HY. Regression of Colonic Adenomas After Treatment With Sulindac in Familial Adenomatous Polyposis: A Case With a 2-Year Follow-up Without a Prophylactic Colectomy. Ann Coloproctol. 2014;30:201-204. [PMID: 25210691 DOI: 10.3393/ac.2014.30.4.201] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
148 Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC, Piazza GA. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009;8:3331-40. [PMID: 19996273 DOI: 10.1158/1535-7163.MCT-09-0758] [Cited by in Crossref: 63] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
149 Ornstein DL, Cohn KH. Balance between activation and inhibition of matrix metalloproteinase-2 (MMP-2) is altered in colorectal tumors compared to normal colonic epithelium. Dig Dis Sci 2002;47:1821-30. [PMID: 12184536 DOI: 10.1023/a:1016456914723] [Cited by in Crossref: 15] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
150 Garcia-Albeniz X, Chan AT. Aspirin for the prevention of colorectal cancer. Best Pract Res Clin Gastroenterol. 2011;25:461-472. [PMID: 22122763 DOI: 10.1016/j.bpg.2011.10.015] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
151 Berquin IM, Edwards IJ, Chen YQ. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008;269:363-77. [PMID: 18479809 DOI: 10.1016/j.canlet.2008.03.044] [Cited by in Crossref: 256] [Cited by in F6Publishing: 217] [Article Influence: 18.3] [Reference Citation Analysis]
152 Litalien C, Jacqz-Aigrain E. Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol. Paediatr Drugs 2001;3:817-58. [PMID: 11735667 DOI: 10.2165/00128072-200103110-00004] [Cited by in Crossref: 105] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
153 Sikandar SS, Pate KT, Anderson S, Dizon D, Edwards RA, Waterman ML, Lipkin SM. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010;70:1469-1478. [PMID: 20145124 DOI: 10.1158/0008-5472.can-09-2557] [Cited by in Crossref: 195] [Cited by in F6Publishing: 125] [Article Influence: 16.3] [Reference Citation Analysis]
154 Yamada Y, Yoshimi N, Hirose Y, Hara A, Shimizu M, Kuno T, Katayama M, Qiao Z, Mori H. Suppression of occurrence and advancement of beta-catenin-accumulated crypts, possible premalignant lesions of colon cancer, by selective cyclooxygenase-2 inhibitor, celecoxib. Jpn J Cancer Res. 2001;92:617-623. [PMID: 11429049 DOI: 10.1111/j.1349-7006.2001.tb01139.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
155 Müller AD, Sonnenberg A, Wasserman IH. Diseases preceding colon cancer. A case-control study among veterans. Dig Dis Sci 1994;39:2480-4. [PMID: 7956619 DOI: 10.1007/BF02087670] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
156 Guillen-Ahlers H, Buechler SA, Suckow MA, Castellino FJ, Ploplis VA. Sulindac treatment alters collagen and matrilysin expression in adenomas of ApcMin/+ mice. Carcinogenesis. 2008;29:1421-1427. [PMID: 18499699 DOI: 10.1093/carcin/bgn123] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
157 Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci U S A 1997;94:657-62. [PMID: 9012840 DOI: 10.1073/pnas.94.2.657] [Cited by in Crossref: 218] [Cited by in F6Publishing: 217] [Article Influence: 8.7] [Reference Citation Analysis]
158 Egashira I, Takahashi-Yanaga F, Nishida R, Arioka M, Igawa K, Tomooka K, Nakatsu Y, Tsuzuki T, Nakabeppu Y, Kitazono T, Sasaguri T. Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway. Cancer Sci 2017;108:108-15. [PMID: 27761963 DOI: 10.1111/cas.13106] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
159 Myung SJ, Rerko RM, Yan M, Platzer P, Guda K, Dotson A, Lawrence E, Dannenberg AJ, Lovgren AK, Luo G, Pretlow TP, Newman RA, Willis J, Dawson D, Markowitz SD. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci U S A 2006;103:12098-102. [PMID: 16880406 DOI: 10.1073/pnas.0603235103] [Cited by in Crossref: 182] [Cited by in F6Publishing: 167] [Article Influence: 11.4] [Reference Citation Analysis]
160 Chan AT. Aspirin and familial adenomatous polyposis: coming full circle. Cancer Prev Res (Phila). 2011;4:623-627. [PMID: 21543340 DOI: 10.1158/1940-6207.capr-11-0157] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
161 Wendum D, Masliah J, Trugnan G, Fléjou JF. Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch. 2004;445:327-333. [PMID: 15340847 DOI: 10.1007/s00428-004-1105-2] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 3.5] [Reference Citation Analysis]
162 O'Brien DP 4th. Polyps in the ileal pouch. Clin Colon Rectal Surg 2008;21:300-3. [PMID: 20011442 DOI: 10.1055/s-0028-1089946] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
163 Roman CD, Morrow J, Whitehead R, Beauchamp RD. Induction of cyclooxygenase-2 and invasiveness by transforming growth factor-beta(1) in immortalized mouse colonocytes expressing oncogenic Ras. J Gastrointest Surg. 2002;6:304-309. [PMID: 12022979 DOI: 10.1016/s1091-255x(01)00041-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
164 Akporiaye ET, Bradley-Dunlop D, Gendler SJ, Mukherjee P, Madsen CS, Hahn T, Besselsen DG, Dial SM, Cui H, Trevor K. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas. Vaccine 2007;25:6965-74. [PMID: 17707958 DOI: 10.1016/j.vaccine.2007.06.063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
165 Kandil HM, Tanner G, Smalley W, Halter S, Radhika A, Dubois RN. Cyclooxygenase-2 expression in Barrett's esophagus. Dig Dis Sci 2001;46:785-9. [PMID: 11330414 DOI: 10.1023/a:1010700400960] [Cited by in Crossref: 66] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
166 Fang HM, Mei Q, Xu JM, Ma WJ. 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitroWorld J Gastroenterol 2007; 13(20): 2872-2877 [PMID: 17569127 DOI: 10.3748/wjg.v13.i20.2872] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
167 Ryoo HD, Bergmann A. The role of apoptosis-induced proliferation for regeneration and cancer. Cold Spring Harb Perspect Biol 2012;4:a008797. [PMID: 22855725 DOI: 10.1101/cshperspect.a008797] [Cited by in Crossref: 112] [Cited by in F6Publishing: 124] [Article Influence: 11.2] [Reference Citation Analysis]
168 Morishita Y, Yoshimi N, Kawabata K, Matsunaga K, Sugie S, Tanaka T, Mori H. Regressive effects of various chemopreventive agents on azoxymethane-induced aberrant crypt foci in the rat colon. Jpn J Cancer Res 1997;88:815-20. [PMID: 9369928 DOI: 10.1111/j.1349-7006.1997.tb00456.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
169 Grau MV, Sandler RS, McKeown-Eyssen G, Bresalier RS, Haile RW, Barry EL, Ahnen DJ, Gui J, Summers RW, Baron JA. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;101:267-276. [PMID: 19211442 DOI: 10.1093/jnci/djn484] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
170 Kanik EA, Canbaz H, Colak T, Aydin S. Chemopreventive effect of nonsteroidal anti-inflammatory drugs on the development of a new colorectal polyp or adenoma in a high-risk population: a meta-analysis. Curr Ther Res Clin Exp 2004;65:345-52. [PMID: 24672089 DOI: 10.1016/j.curtheres.2004.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 Lee K, A Piazza G. The interaction between the Wnt/β-catenin signaling cascade and PKG activation in cancer. J Biomed Res 2017;31:189-96. [PMID: 28808213 DOI: 10.7555/JBR.31.20160133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
172 Mohammed A, Yarla NS, Madka V, Rao CV. Clinically Relevant Anti-Inflammatory Agents for Chemoprevention of Colorectal Cancer: New Perspectives. Int J Mol Sci 2018;19:E2332. [PMID: 30096840 DOI: 10.3390/ijms19082332] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
173 Le PN, McDermott JD, Jimeno A. Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther. 2015;146:1-11. [PMID: 25172549 DOI: 10.1016/j.pharmthera.2014.08.005] [Cited by in Crossref: 126] [Cited by in F6Publishing: 120] [Article Influence: 15.8] [Reference Citation Analysis]
174 Rice PFS, Ehrichs KG, Jones MS, Chen H, Hsu CH, Abril ER, Nagle RB, Besselsen DG, Barton JK, Ignatenko NA. Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? Cancer Prev Res (Phila) 2018;11:16-26. [PMID: 29118162 DOI: 10.1158/1940-6207.CAPR-17-0230] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
175 Chang WL, Jackson C, Riel S, Cooper HS, Devarajan K, Hensley HH, Zhou Y, Vanderveer LA, Nguyen MT, Clapper ML. Differential preventive activity of sulindac and atorvastatin in Apc+/Min-FCCCmice with or without colorectal adenomas. Gut 2018;67:1290-8. [PMID: 29122850 DOI: 10.1136/gutjnl-2017-313942] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
176 Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY. Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol 2008;622:99-117. [PMID: 18546622 DOI: 10.1007/978-0-387-68969-2_9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
177 Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut. 1997;40:344-349. [PMID: 9135523 DOI: 10.1136/gut.40.3.344] [Cited by in Crossref: 63] [Cited by in F6Publishing: 48] [Article Influence: 2.5] [Reference Citation Analysis]
178 Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin 2015;65:345-83. [PMID: 26284997 DOI: 10.3322/caac.21287] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
179 Greenspan EJ, Nichols FC, Rosenberg DW. Molecular alterations associated with sulindac-resistant colon tumors in ApcMin/+ mice. Cancer Prev Res (Phila) 2010;3:1187-97. [PMID: 20716632 DOI: 10.1158/1940-6207.CAPR-09-0270] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
180 Yi B, Cheng H, Wyczechowska D, Yu Q, Li L, Ochoa AC, Riker AI, Xi Y. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy. Mol Cancer Ther 2021;20:1295-304. [PMID: 33879557 DOI: 10.1158/1535-7163.MCT-20-0934] [Reference Citation Analysis]
181 Akre K, Ekström AM, Signorello LB, Hansson LE, Nyrén O. Aspirin and risk for gastric cancer: a population-based case-control study in Sweden. Br J Cancer. 2001;84:965-968. [PMID: 11286478 DOI: 10.1054/bjoc.2001.1702] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 5.0] [Reference Citation Analysis]
182 Telang N. Stem cell models for genetically predisposed colon cancer. Oncol Lett 2020;20:138. [PMID: 32934706 DOI: 10.3892/ol.2020.11998] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
183 Kim B, Giardiello FM. Chemoprevention in familial adenomatous polyposis. Best Pract Res Clin Gastroenterol. 2011;25:607-622. [PMID: 22122775 DOI: 10.1016/j.bpg.2011.08.002] [Cited by in Crossref: 62] [Cited by in F6Publishing: 54] [Article Influence: 6.2] [Reference Citation Analysis]
184 Yasuda H, Yamada M, Endo Y, Inoue K, Yoshiba M. Elevated cyclooxygenase-2 expression in patients with early gastric cancer in the gastric pylorus. J Gastroenterol. 2005;40:690-697. [PMID: 16082585 DOI: 10.1007/s00535-005-1612-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
185 Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22. [PMID: 19822006 DOI: 10.1186/1750-1172-4-22] [Cited by in Crossref: 261] [Cited by in F6Publishing: 223] [Article Influence: 20.1] [Reference Citation Analysis]
186 Bastakoty D, Young PP. Wnt/β-catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration. FASEB J 2016;30:3271-84. [PMID: 27335371 DOI: 10.1096/fj.201600502R] [Cited by in Crossref: 59] [Cited by in F6Publishing: 33] [Article Influence: 9.8] [Reference Citation Analysis]
187 Arber N, Kuwada S, Leshno M, Sjodahl R, Hultcrantz R, Rex D. Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study. Gut. 2006;55:367-373. [PMID: 16150858 DOI: 10.1136/gut.2004.061432] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
188 Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prev Res (Phila). 2011;4:259-269. [PMID: 21209397 DOI: 10.1158/1940-6207.CAPR-10-0215] [Cited by in Crossref: 46] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
189 Koutsos MI, Shiff SJ, Rigas B. Can nonsteroidal anti-inflammatory drugs be recommended to prevent colon cancer in high risk elderly patients. Drugs Aging. 1995;6:421-425. [PMID: 7663061 DOI: 10.2165/00002512-199506060-00001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
190 Park W, Amin AR, Chen ZG, Shin DM. New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013;6:387-400. [PMID: 23466484 DOI: 10.1158/1940-6207.capr-12-0410] [Cited by in Crossref: 144] [Cited by in F6Publishing: 68] [Article Influence: 16.0] [Reference Citation Analysis]
191 Lynch PM. Chemoprevention of familial adenomatous polyposis. Fam Cancer 2016;15:467-75. [PMID: 27083160 DOI: 10.1007/s10689-016-9901-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 4.2] [Reference Citation Analysis]
192 Phillips RK, Wallace MH, Lynch PM, Hawk E, Gordon GB, Saunders BP, Wakabayashi N, Shen Y, Zimmerman S, Godio L. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857-860. [PMID: 12010890 DOI: 10.1136/gut.50.6.857] [Cited by in Crossref: 284] [Cited by in F6Publishing: 227] [Article Influence: 14.2] [Reference Citation Analysis]
193 Yin T, Wang G, Ye T, Wang Y. Sulindac, a non-steroidal anti-inflammatory drug, mediates breast cancer inhibition as an immune modulator. Sci Rep 2016;6:19534. [PMID: 26777116 DOI: 10.1038/srep19534] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
194 Ettarh R, Cullen A, Calamai A. NSAIDs and Cell Proliferation in Colorectal Cancer. Pharmaceuticals (Basel) 2010;3:2007-21. [PMID: 27713339 DOI: 10.3390/ph3072007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
195 Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest. 1995;96:491503. [PMID: 7615821 DOI: 10.1172/jci118060] [Cited by in Crossref: 267] [Cited by in F6Publishing: 59] [Article Influence: 9.9] [Reference Citation Analysis]
196 Hallak A, Alon-Baron L, Shamir R, Moshkowitz M, Bulvik B, Brazowski E, Halpern Z, Arber N. Rofecoxib reduces polyp recurrence in familial polyposis. Dig Dis Sci 2003;48:1998-2002. [PMID: 14627347 DOI: 10.1023/a:1026130623186] [Cited by in Crossref: 59] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
197 Oshima H, Oshima M. The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol. 2013;35:139-150. [PMID: 23053397 DOI: 10.1007/s00281-012-0353-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
198 Reddy BS, Rao CV. Chemoprophylaxis of colon cancer. Curr Gastroenterol Rep 2005;7:389-95. [PMID: 16168238 DOI: 10.1007/s11894-005-0009-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
199 Amini-Nik S, Yousuf Y, Jeschke MG. Scar management in burn injuries using drug delivery and molecular signaling: Current treatments and future directions. Adv Drug Deliv Rev 2018;123:135-54. [PMID: 28757325 DOI: 10.1016/j.addr.2017.07.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
200 Cavallari C, Tarterini F, Fini A. Thermal characterization of some polymorph solvates of the anti-inflammatory/anti-cancer sulindac. Thermochimica Acta 2016;633:129-39. [DOI: 10.1016/j.tca.2016.01.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
201 Yi B, Chang H, Ma R, Feng X, Li W, Piazza GA, Xi Y. Inhibition of breast cancer cell motility with a non-cyclooxygenase inhibitory derivative of sulindac by suppressing TGFβ/miR-21 signaling. Oncotarget 2016;7:7979-92. [PMID: 26769851 DOI: 10.18632/oncotarget.6888] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
202 Itano O, Yang K, Fan K, Kurihara N, Shinozaki H, Abe S, Jin B, Gravaghi C, Edelmann W, Augenlicht L, Kopelovich L, Kucherlapati R, Lamprecht S, Lipkin M. Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis 2009;30:1923-6. [PMID: 19755659 DOI: 10.1093/carcin/bgp200] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
203 Burke CA, Phillips R, Berger MF, Li C, Essex MN, Iorga D, Lynch PM. Children's International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol 2017;10:177-85. [PMID: 28765715 DOI: 10.2147/CEG.S121841] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
204 Bertagnolli MM. Cyclooxygenase-2 and Chronic Inflammation: Drivers of Colorectal Tumorigenesis. In: Markowitz SD, Berger NA, editors. Energy Balance and Gastrointestinal Cancer. Boston: Springer US; 2012. pp. 157-82. [DOI: 10.1007/978-1-4614-2367-6_10] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
205 Chang CK, Ulrich CM. Hyperinsulinaemia and hyperglycaemia: possible risk factors of colorectal cancer among diabetic patients. Diabetologia. 2003;46:595-607. [PMID: 12764580 DOI: 10.1007/s00125-003-1109-5] [Cited by in Crossref: 71] [Cited by in F6Publishing: 61] [Article Influence: 3.7] [Reference Citation Analysis]
206 Gerner EW. Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models. Biochem Soc Trans. 2007;35:322-325. [PMID: 17371270 DOI: 10.1042/bst0350322] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
207 Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011;17:405-415. [PMID: 22157284 DOI: 10.1097/ppo.0b013e318237e408] [Cited by in Crossref: 71] [Cited by in F6Publishing: 32] [Article Influence: 7.1] [Reference Citation Analysis]
208 Park JH, Kang KH, Kim SH, Lee JH, Cho CM, Kweon YO, Kim SK, Choi YH, Bae HI, Kim MS. Expression of Cyclooxygenase-2 and Bcl-2 in human gastric adenomas. Korean J Intern Med. 2005;20:198-204. [PMID: 16295777 DOI: 10.3904/kjim.2005.20.3.198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
209 Half EE, Bresalier RS. Treatment of Hereditary Colorectal Cancer Syndromes. Curr Treat Options Gastroenterol 2004;7:213-24. [PMID: 15149583 DOI: 10.1007/s11938-004-0042-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Kuno T, Yamada Y, Hirose Y, Katayama M, Sakata K, Hara A, Saji S, Mori H. Induction of apoptosis by sulindac in azoxymethane-induced possible colonic premalignant lesions in rats. Jpn J Cancer Res 2002;93:242-6. [PMID: 11927004 DOI: 10.1111/j.1349-7006.2002.tb02164.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
211 Goessling W, North TE, Loewer S, Lord AM, Lee S, Stoick-Cooper CL, Weidinger G, Puder M, Daley GQ, Moon RT. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009;136:1136-1147. [PMID: 19303855 DOI: 10.1016/j.cell.2009.01.015] [Cited by in Crossref: 495] [Cited by in F6Publishing: 485] [Article Influence: 38.1] [Reference Citation Analysis]
212 Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011;7:651-8. [PMID: 21647333 DOI: 10.7150/ijbs.7.651] [Cited by in Crossref: 350] [Cited by in F6Publishing: 337] [Article Influence: 31.8] [Reference Citation Analysis]
213 Patel NJ, Ponugoti PL, Rex DK. Cold snare polypectomy effectively reduces polyp burden in familial adenomatous polyposis. Endosc Int Open 2016;4:E472-4. [PMID: 27092331 DOI: 10.1055/s-0042-104114] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
214 Ochiai M, Oguri T, Isobe T, Ishioka S, Yamakido M. Cyclooxygenase-2 (COX-2) mRNA expression levels in normal lung tissues and non-small cell lung cancers. Jpn J Cancer Res. 1999;90:1338-1343. [PMID: 10665651 DOI: 10.1111/j.1349-7006.1999.tb00717.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 47] [Article Influence: 2.2] [Reference Citation Analysis]
215 Janakiram NB, Mohammed A, Qian L, Choi CI, Steele VE, Rao CV. Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia 2012;14:159-68. [PMID: 22431924 DOI: 10.1593/neo.111440] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
216 Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci. 1996;93:7950-7954. [PMID: 8755583 DOI: 10.1073/pnas.93.15.7950] [Cited by in Crossref: 308] [Cited by in F6Publishing: 312] [Article Influence: 11.8] [Reference Citation Analysis]
217 Tomita N, Ishida H, Tanakaya K, Yamaguchi T, Kumamoto K, Tanaka T, Hinoi T, Miyakura Y, Hasegawa H, Takayama T, Ishikawa H, Nakajima T, Chino A, Shimodaira H, Hirasawa A, Nakayama Y, Sekine S, Tamura K, Akagi K, Kawasaki Y, Kobayashi H, Arai M, Itabashi M, Hashiguchi Y, Sugihara K; Japanese Society for Cancer of the Colon, Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2020 for the Clinical Practice of Hereditary Colorectal Cancer. Int J Clin Oncol 2021;26:1353-419. [PMID: 34185173 DOI: 10.1007/s10147-021-01881-4] [Reference Citation Analysis]
218 Bakhle YS. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol. 2001;134:1137-1150. [PMID: 11704632 DOI: 10.1038/sj.bjp.0704365] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 4.0] [Reference Citation Analysis]
219 Giardiello FM, Yang VW, Hylind LM, Krush AJ, Petersen GM, Trimbath JD, Piantadosi S, Garrett E, Geiman DE, Hubbard W. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med. 2002;346:1054-1059. [PMID: 11932472 DOI: 10.1056/nejmoa012015] [Cited by in Crossref: 264] [Cited by in F6Publishing: 77] [Article Influence: 13.2] [Reference Citation Analysis]
220 Tinsley HN, Grizzle WE, Abadi A, Keeton A, Zhu B, Xi Y, Piazza GA. New NSAID targets and derivatives for colorectal cancer chemoprevention. Recent Results Cancer Res 2013;191:105-20. [PMID: 22893202 DOI: 10.1007/978-3-642-30331-9_6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
221 Kömhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO, Shappell SB, Breyer MD. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000;157:29-35. [PMID: 10880372 DOI: 10.1016/S0002-9440(10)64513-0] [Cited by in Crossref: 110] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
222 Shureiqi I, Jiang W, Zuo X, Wu Y, Stimmel JB, Leesnitzer LM, Morris JS, Fan HZ, Fischer SM, Lippman SM. The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci USA. 2003;100:9968-9973. [PMID: 12909723 DOI: 10.1073/pnas.1631086100] [Cited by in Crossref: 160] [Cited by in F6Publishing: 142] [Article Influence: 8.4] [Reference Citation Analysis]
223 Yan M, Rerko RM, Platzer P, Dawson D, Willis J, Tong M, Lawrence E, Lutterbaugh J, Lu S, Willson JK. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci USA. 2004;101:17468-17473. [PMID: 15574495 DOI: 10.1073/pnas.0406142101] [Cited by in Crossref: 179] [Cited by in F6Publishing: 158] [Article Influence: 9.9] [Reference Citation Analysis]
224 Arber N, DuBois RN. Nonsteroidal anti-inflammatory drugs and prevention of colorectal cancer. Curr Gastroenterol Rep. 1999;1:441-448. [PMID: 10980984 DOI: 10.1007/s11894-999-0027-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.1] [Reference Citation Analysis]
225 Ma H, Brosens LAA, Elias SG, Morsink FHM, Nijman IJ, Hylind LM, Montgomery EA, Offerhaus GJA, Giardiello FM, de Leng WWJ. Longitudinal analysis of colon crypt stem cell dynamics in sulindac treated Familial Adenomatous Polyposis patients. Sci Rep 2017;7:11972. [PMID: 28931879 DOI: 10.1038/s41598-017-11865-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
226 Edwards RA, Wang K, Davis JS, Birnbaumer L. Role for epithelial dysregulation in early-onset colitis-associated colon cancer in Gi2-alpha-/- mice. Inflamm Bowel Dis 2008;14:898-907. [PMID: 18340649 DOI: 10.1002/ibd.20414] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
227 Kumar AP, Lukman S. Allosteric binding sites in Rab11 for potential drug candidates. PLoS One 2018;13:e0198632. [PMID: 29874286 DOI: 10.1371/journal.pone.0198632] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
228 Morgan GP, Williams JG. Therapeutic potential of aspirin in cancer of the colon. BMJ 1993;307:1007-8. [PMID: 8204142 DOI: 10.1136/bmj.307.6910.1007-b] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
229 Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtulla A, Beer DG. Indomethacin-induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia. 2000;2:346-356. [PMID: 11005569 DOI: 10.1038/sj.neo.7900097] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 2.5] [Reference Citation Analysis]
230 Lee HM, Cha JM, Lee JL, Jeon JW, Shin HP, Joo KR, Yoon JY, Lee JI. High C-reactive protein level is associated with high-risk adenoma. Intest Res 2017;15:511-7. [PMID: 29142519 DOI: 10.5217/ir.2017.15.4.511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
231 Morgan G. Non-steroidal anti-inflammatory drugs and the chemoprevention of colorectal and oesophageal cancers. Gut. 1996;38:646-648. [PMID: 8707106 DOI: 10.1136/gut.38.5.646] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
232 Huang RH, Chai J, Tarnawski AS. Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. World J Gastroenterol 2006; 12(40): 6446-6452 [PMID: 17072976 DOI: 10.3748/wjg.v12.i40.6446] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
233 Macaron C, Mankaney GN, Haider M, Mouchli M, Hurley K, Burke CA. Chemoprevention Considerations in Patients with Hereditary Colorectal Cancer Syndromes. Gastrointest Endosc Clin N Am 2022;32:131-46. [PMID: 34798982 DOI: 10.1016/j.giec.2021.08.005] [Reference Citation Analysis]
234 Babbar N, Gerner EW. Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res 2011;188:49-64. [PMID: 21253788 DOI: 10.1007/978-3-642-10858-7_4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
235 Zell JA. Clinical trials update: Tertiary prevention of colorectal cancer. J Carcinog 2011;10:8. [PMID: 21483656 DOI: 10.4103/1477-3163.78271] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
236 Serrano D, Bonanni B, Brown K. Therapeutic cancer prevention: achievements and ongoing challenges - a focus on breast and colorectal cancer. Mol Oncol 2019;13:579-90. [PMID: 30690875 DOI: 10.1002/1878-0261.12461] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
237 Jolly K, Cheng KK, Langman MJ. NSAIDs and gastrointestinal cancer prevention. Drugs. 2002;62:945-956. [PMID: 11929340 DOI: 10.2165/00003495-200262060-00006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
238 Wickström M, Dyberg C, Milosevic J, Einvik C, Calero R, Sveinbjörnsson B, Sandén E, Darabi A, Siesjö P, Kool M, Kogner P, Baryawno N, Johnsen JI. Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance. Nat Commun 2015;6:8904. [PMID: 26603103 DOI: 10.1038/ncomms9904] [Cited by in Crossref: 110] [Cited by in F6Publishing: 105] [Article Influence: 15.7] [Reference Citation Analysis]
239 Calabrese C, Praticò C, Calafiore A, Coscia M, Gentilini L, Poggioli G, Gionchetti P, Campieri M, Rizzello F. Eviendep® reduces number and size of duodenal polyps in familial adenomatous polyposis patients with ileal pouch-anal anastomosis. World J Gastroenterol 2013; 19(34): 5671-5677 [PMID: 24039360 DOI: 10.3748/wjg.v19.i34.5671] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
240 Hwang DH, Fung V, Dannenberg AJ. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and -independent mechanisms. Neoplasia 2002;4:91-7. [PMID: 11896563 DOI: 10.1038/sj.neo.7900226] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 2.1] [Reference Citation Analysis]
241 Nakatsugi S, Fukutake M, Takahashi M, Fukuda K, Isoi T, Taniguchi Y, Sugimura T, Wakabayashi K. Suppression of intestinal polyp development by nimesulide, a selective cyclooxygenase-2 inhibitor, in Min mice. Jpn J Cancer Res. 1997;88:1117-1120. [PMID: 9473726 DOI: 10.1111/j.1349-7006.1997.tb00337.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 55] [Article Influence: 2.5] [Reference Citation Analysis]
242 Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, Maruyama T, Sugimoto Y, Negishi M, Narumiya S, Sugimura T, Wakabayashi K. Downregulation of prostaglandin E receptor subtype EP3 during colon cancer development. Gut 2004;53:1151-8. [PMID: 15247185 DOI: 10.1136/gut.2003.028787] [Cited by in Crossref: 108] [Cited by in F6Publishing: 99] [Article Influence: 6.0] [Reference Citation Analysis]
243 Lee JS, Kim HS, Hahm KB, Surh YJ. Effects of Genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated Carcinogenesis in Mice. J Cancer Prev 2020;25:27-37. [PMID: 32266177 DOI: 10.15430/JCP.2020.25.1.27] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
244 Langman M, Boyle P. Chemoprevention of colorectal cancer. Gut 1998;43:578-85. [PMID: 9824590 DOI: 10.1136/gut.43.4.578] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
245 Reddy BS, Rao CV. Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs. Drugs Aging 2000;16:329-34. [PMID: 10917070 DOI: 10.2165/00002512-200016050-00002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
246 Demols A, Van Laethem JL. Adjuvant chemotherapy for colorectal cancer. Curr Gastroenterol Rep. 2002;4:420-426. [PMID: 12228045 DOI: 10.1007/s11894-002-0013-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
247 Xi Y. MicroRNA: A New Player for Cancer Chemoprevention. J Integr Oncol 2013;2:105. [PMID: 24236300 DOI: 10.4172/2329-6771.1000105] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
248 Cherukuri DP, Ishikawa TO, Chun P, Catapang A, Elashoff D, Grogan TR, Bugni J, Herschman HR. Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice. Mol Oncol 2014;8:169-77. [PMID: 24268915 DOI: 10.1016/j.molonc.2013.10.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
249 Hindi Muñiz N, Lamarca Lete A, Feliú Batlle J. [Hereditary colorectal cancer]. Med Clin (Barc) 2012;138:220-3. [PMID: 22093404 DOI: 10.1016/j.medcli.2011.09.019] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
250 Zell JA, Ziogas A, Bernstein L, Clarke CA, Deapen D, Largent JA, Neuhausen SL, Stram DO, Ursin G, Anton-Culver H. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 2009;115:5662-71. [PMID: 19827153 DOI: 10.1002/cncr.24705] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.4] [Reference Citation Analysis]
251 Hernandez Y, Sotolongo J, Breglio K, Conduah D, Chen A, Xu R, Hsu D, Ungaro R, Hayes LA, Pastorini C. The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol. 2010;10:82. [PMID: 20637112 DOI: 10.1186/1471-230X-10-82] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
252 Zimmerman ZF, Moon RT, Chien AJ. Targeting Wnt pathways in disease. Cold Spring Harb Perspect Biol 2012;4:a008086. [PMID: 23001988 DOI: 10.1101/cshperspect.a008086] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 6.7] [Reference Citation Analysis]
253 Lang M, Gasche C. Chemoprevention of colorectal cancer. Dig Dis 2015;33:58-67. [PMID: 25531498 DOI: 10.1159/000366037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
254 Bowen CM, Walter L, Borras E, Wu W, Ozcan Z, Chang K, Bommi PV, Taggart MW, Thirumurthi S, Lynch PM, Reyes-Uribe L, Scheet PA, Sinha KM, Vilar E. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis. Cancer Prev Res (Phila) 2021;14:851-62. [PMID: 34266857 DOI: 10.1158/1940-6207.CAPR-20-0496] [Reference Citation Analysis]
255 Henry CJ, Sedjo RL, Rozhok A, Salstrom J, Ahnen D, Levin TR, D’Agostino R, Haffner S, DeGregori J, Byers T. Lack of significant association between serum inflammatory cytokine profiles and the presence of colorectal adenoma. BMC Cancer. 2015;15:123. [PMID: 25884547 DOI: 10.1186/s12885-015-1115-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
256 Shappell SB, Manning S, Boeglin WE, Guan YF, Roberts RL, Davis L, Olson SJ, Jack GS, Coffey CS, Wheeler TM, Breyer MD, Brash AR. Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. Neoplasia 2001;3:287-303. [PMID: 11571629 DOI: 10.1038/sj.neo.7900166] [Cited by in Crossref: 79] [Cited by in F6Publishing: 70] [Article Influence: 3.8] [Reference Citation Analysis]
257 van Hattem WA, Brosens LA, Marks SY, Milne AN, van Eeden S, Iacobuzio-Donahue CA, Ristimäki A, Giardiello FM, Offerhaus GJ. Increased cyclooxygenase-2 expression in juvenile polyposis syndrome. Clin Gastroenterol Hepatol. 2009;7:93-97. [PMID: 19124115 DOI: 10.1016/j.cgh.2008.07.030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
258 Sangha S, Yao M, Wolfe MM. Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad Med J 2005;81:223-7. [PMID: 15811884 DOI: 10.1136/pgmj.2003.008227] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
259 Verheul HM, Panigrahy D, Yuan J, D'Amato RJ. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer. 1999;79:114-118. [PMID: 10408702 DOI: 10.1038/sj.bjc.6690020] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.0] [Reference Citation Analysis]
260 Rossi DJ, Ylikorkala A, Korsisaari N, Salovaara R, Luukko K, Launonen V, Henkemeyer M, Ristimaki A, Aaltonen LA, Makela TP. Induction of cyclooxygenase-2 in a mouse model of Peutz-Jeghers polyposis. Proc Natl Acad Sci U S A. 2002;99:12327-12332. [PMID: 12218179 DOI: 10.1073/pnas.192301399] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 4.2] [Reference Citation Analysis]
261 Mujtaba S, Bostick RM. Differences in risk factor-colorectal adenoma associations according to non-steroidal anti-inflammatory drug use. Eur J Gastroenterol Hepatol 2018;30:1318-26. [PMID: 30161027 DOI: 10.1097/MEG.0000000000001252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
262 Li N, Chen X, Zhu B, Ramírez-Alcántara V, Canzoneri JC, Lee K, Sigler S, Gary B, Li Y, Zhang W, Moyer MP, Salter EA, Wierzbicki A, Keeton AB, Piazza GA. Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. Oncotarget 2015;6:27403-15. [PMID: 26299804 DOI: 10.18632/oncotarget.4741] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
263 Samadder NJ, Kuwada SK, Boucher KM, Byrne K, Kanth P, Samowitz W, Jones D, Tavtigian SV, Westover M, Berry T, Jasperson K, Pappas L, Smith L, Sample D, Burt RW, Neklason DW. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2018;4:671-7. [PMID: 29423501 DOI: 10.1001/jamaoncol.2017.5431] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 10.0] [Reference Citation Analysis]
264 Berquin IM, Min Y, Wu R, Wu J, Perry D, Cline JM, Thomas MJ, Thornburg T, Kulik G, Smith A, Edwards IJ, D'Agostino R, Zhang H, Wu H, Kang JX, Chen YQ. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007;117:1866-75. [PMID: 17607361 DOI: 10.1172/JCI31494] [Cited by in Crossref: 175] [Cited by in F6Publishing: 111] [Article Influence: 11.7] [Reference Citation Analysis]
265 DeWeese TL, Shipman JM, Larrier NA, Buckley NM, Kidd LR, Groopman JD, Cutler RG, te Riele H, Nelson WG. Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation. Proc Natl Acad Sci U S A 1998;95:11915-20. [PMID: 9751765 DOI: 10.1073/pnas.95.20.11915] [Cited by in Crossref: 123] [Cited by in F6Publishing: 120] [Article Influence: 5.1] [Reference Citation Analysis]
266 Esplin ED, Snyder MP. Genomic era diagnosis and management of hereditary and sporadic colon cancer. World J Clin Oncol 2014; 5(5): 1036-1047 [PMID: 25493239 DOI: 10.5306/wjco.v5.i5.1036] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
267 Telang N. Anti-inflammatory drug resistance selects putative cancer stem cells in a cellular model for genetically predisposed colon cancer. Oncol Lett 2018;15:642-8. [PMID: 29434827 DOI: 10.3892/ol.2017.7147] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
268 Howe LR, Dannenberg AJ. COX-2 inhibitors for the prevention of breast cancer. J Mammary Gland Biol Neoplasia 2003;8:31-43. [PMID: 14587862 DOI: 10.1023/a:1025731204719] [Cited by in Crossref: 41] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
269 O’brien MJ, Gibbons D. The Adenoma-carcinoma Sequence in Colorectal Neoplasia. Surgical Oncology Clinics of North America 1996;5:513-30. [DOI: 10.1016/s1055-3207(18)30361-2] [Cited by in Crossref: 6] [Article Influence: 0.2] [Reference Citation Analysis]
270 Friederich P, Verschuur J, van Heumen BW, Roelofs HM, Berkhout M, Nagtegaal ID, van Oijen MG, van Krieken JH, Peters WH, Nagengast FM. Effects of intervention with sulindac and inulin/VSL#3 on mucosal and luminal factors in the pouch of patients with familial adenomatous polyposis. Int J Colorectal Dis. 2011;26:575-582. [PMID: 21243500 DOI: 10.1007/s00384-010-1127-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
271 Wang Q, Fan LY, He J, Wang YH. Inhibitory effect of sulindac against chemically-induced primary colonic tumors by N-methyl-N-nitrosourea in mice. World J Gastroenterol 1997; 3(1): 16-18 [PMID: 27006576 DOI: 10.3748/wjg.v3.i1.16] [Reference Citation Analysis]
272 Brandão RD, Veeck J, Van de Vijver KK, Lindsey P, de Vries B, van Elssen CH, Blok MJ, Keymeulen K, Ayoubi T, Smeets HJ, Tjan-Heijnen VC, Hupperets PS. A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res 2013;15:R29. [PMID: 23566419 DOI: 10.1186/bcr3409] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
273 Campos FG, Sulbaran M, Safatle-Ribeiro AV, Martinez CAR. Duodenal adenoma surveillance in patients with familial adenomatous polyposis. World J Gastrointest Endosc 2015; 7(10): 950-959 [PMID: 26265988 DOI: 10.4253/wjge.v7.i10.950] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
274 Quesada CF, Kimata H, Mori M, Nishimura M, Tsuneyoshi T, Baba S. Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice. Jpn J Cancer Res 1998;89:392-6. [PMID: 9617344 DOI: 10.1111/j.1349-7006.1998.tb00576.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 2.2] [Reference Citation Analysis]
275 Oshima H, Oshima M. The role of PGE2-associated inflammatory responses in gastric cancer development. Semin Immunopathol. 2013;35:139-150. [PMID: 23053397 DOI: 10.1007/s00281-] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
276 Hertervig E, Nilsson A, Nilbert M, Duan RD. Reduction in alkaline sphingomyelinase in colorectal tumorigenesis is not related to the APC gene mutation. Int J Colorectal Dis 2003;18:309-13. [PMID: 12774245 DOI: 10.1007/s00384-002-0471-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
277 Nowak-Sliwinska P, Scapozza L, Ruiz i Altaba A. Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochim Biophys Acta Rev Cancer 2019;1871:434-54. [PMID: 31034926 DOI: 10.1016/j.bbcan.2019.04.005] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 22.3] [Reference Citation Analysis]
278 Esbona K, Inman D, Saha S, Jeffery J, Schedin P, Wilke L, Keely P. COX-2 modulates mammary tumor progression in response to collagen density. Breast Cancer Res 2016;18:35. [PMID: 27000374 DOI: 10.1186/s13058-016-0695-3] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 10.3] [Reference Citation Analysis]
279 Hisamuddin IM, Wehbi MA, Schmotzer B, Easley KA, Hylind LM, Giardiello FM, Yang VW. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis. Cancer Epidemiol Biomarkers Prev 2005;14:2366-9. [PMID: 16214918 DOI: 10.1158/1055-9965.EPI-05-0312] [Cited by in Crossref: 35] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
280 Perdiki M, Korkolopoulou P, Thymara I, Agrogiannis G, Piperi C, Boviatsis E, Kotsiakis X, Angelidakis D, Diamantopoulou K, Thomas-Tsagli E, Patsouris E. Cyclooxygenase-2 expression in astrocytomas. Relationship with microvascular parameters, angiogenic factors expression and survival. Mol Cell Biochem 2007;295:75-83. [PMID: 16868662 DOI: 10.1007/s11010-006-9275-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
281 Li N, Xi Y, Tinsley HN, Gurpinar E, Gary BD, Zhu B, Li Y, Chen X, Keeton AB, Abadi AH. Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. Mol Cancer Ther. 2013;12:1848-1859. [PMID: 23804703 DOI: 10.1158/1535-7163.mct-13-0048] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 7.7] [Reference Citation Analysis]
282 Giardiello FM, Spannhake EW, DuBois RN, Hylind LM, Robinson CR, Hubbard WC, Hamilton SR, Yang VW. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Dig Dis Sci. 1998;43:311-316. [PMID: 9512123 DOI: 10.1023/A:1018898120673] [Cited by in Crossref: 62] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
283 Davies NM, Watson MS. Clinical pharmacokinetics of sulindac. A dynamic old drug. Clin Pharmacokinet 1997;32:437-59. [PMID: 9195115 DOI: 10.2165/00003088-199732060-00002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.0] [Reference Citation Analysis]
284 Yip-Schneider MT, Wiesenauer CA, Schmidt CM. Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac. J Gastrointest Surg 2003;7:354-63. [PMID: 12654560 DOI: 10.1016/s1091-255x(02)00156-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
285 Rappaport JA, Waldman SA. An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. Expert Rev Clin Pharmacol 2020;13:1125-37. [PMID: 32945718 DOI: 10.1080/17512433.2020.1826304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
286 Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int J Mol Sci 2020;22:E130. [PMID: 33374459 DOI: 10.3390/ijms22010130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
287 Hayslip J, Chaudhary U, Green M, Meyer M, Dunder S, Sherman C, Salzer S, Kraft A, Montero AJ. Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer 2007;7:221. [PMID: 18053191 DOI: 10.1186/1471-2407-7-221] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
288 Duarte D, Vale N. Combining repurposed drugs to treat colorectal cancer. Drug Discov Today 2021:S1359-6446(21)00406-2. [PMID: 34592446 DOI: 10.1016/j.drudis.2021.09.012] [Reference Citation Analysis]
289 Sui HH, Zhou YJ, Wang H, Li L, Cao M, Huang JJ. Effects of sulindac sulfide on proliferation and apoptosis of human breast cancer cell. Oncol Lett 2018;15:7981-6. [PMID: 29849803 DOI: 10.3892/ol.2018.8331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
290 Sharman SK, Islam BN, Hou Y, Singh N, Berger FG, Sridhar S, Yoo W, Browning DD. Cyclic-GMP-Elevating Agents Suppress Polyposis in ApcMin mice by Targeting the Preneoplastic Epithelium. Cancer Prev Res (Phila) 2018;11:81-92. [PMID: 29301746 DOI: 10.1158/1940-6207.CAPR-17-0267] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
291 Nguyen LH, Goel A, Chung DC. Pathways of Colorectal Carcinogenesis. Gastroenterology 2020;158:291-302. [PMID: 31622622 DOI: 10.1053/j.gastro.2019.08.059] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
292 Sozen S, Gurocak S, Erdem O, Acar C, Kordan Y, Akyol G, Alkibay T. Cyclooxygenase-2 expression: does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma? Int Urol Nephrol 2008;40:295-301. [PMID: 17899436 DOI: 10.1007/s11255-007-9268-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
293 Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-9. [PMID: 8374373 DOI: 10.1136/bmj.307.6899.285] [Cited by in Crossref: 180] [Cited by in F6Publishing: 150] [Article Influence: 6.2] [Reference Citation Analysis]
294 Ruder EH, Laiyemo AO, Graubard BI, Hollenbeck AR, Schatzkin A, Cross AJ. Non-steroidal anti-inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol. 2011;106:1340-1350. [PMID: 21407185 DOI: 10.1038/ajg.2011.38ajg201138] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
295 Jiang JG, Tang JB, Chen CL, Liu BX, Fu XN, Zhu ZH, Qu W, Cianflone K, Waalkes MP, Wang DW. Expression of cyclooxygenase-2 in human esophageal squamous cell carcinomas. World J Gastroenterol 2004; 10(15): 2168-2173 [PMID: 15259059 DOI: 10.3748/wjg.v10.i15.2168] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
296 Fischer SM, Hawk ET, Lubet RA. Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila). 2011;4:1728-1735. [PMID: 21778329 DOI: 10.1158/1940-6207.capr-11-0166] [Cited by in Crossref: 83] [Cited by in F6Publishing: 50] [Article Influence: 7.5] [Reference Citation Analysis]
297 Kutchera W, Jones DA, Matsunami N, Groden J, McIntyre TM, Zimmerman GA, White RL, Prescott SM. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA. 1996;93:4816-4820. [PMID: 8643486 DOI: 10.1073/pnas.93.10.4816] [Cited by in Crossref: 293] [Cited by in F6Publishing: 286] [Article Influence: 11.3] [Reference Citation Analysis]
298 Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11-26. [PMID: 23258168 DOI: 10.1038/nrc3419] [Cited by in Crossref: 1221] [Cited by in F6Publishing: 1200] [Article Influence: 135.7] [Reference Citation Analysis]
299 Pasanisi P, Gariboldi M, Verderio P, Signoroni S, Mancini A, Rivoltini L, Milione M, Masci E, Ciniselli CM, Bruno E, Macciotta A, Belfiore A, Ricci MT, Gargano G, Morelli D, Apolone G, Vitellaro M. A Pilot Low-Inflammatory Dietary Intervention to Reduce Inflammation and Improve Quality of Life in Patients With Familial Adenomatous Polyposis: Protocol Description and Preliminary Results. Integr Cancer Ther. 2019;18:1534735419846400. [PMID: 31055940 DOI: 10.1177/1534735419846400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
300 Aihara H, Kumar N, Thompson CC. Diagnosis, surveillance, and treatment strategies for familial adenomatous polyposis: rationale and update. Eur J Gastroenterol Hepatol 2014;26:255-62. [PMID: 24161962 DOI: 10.1097/MEG.0000000000000010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
301 Piazza GA, Ward A, Chen X, Maxuitenko Y, Coley A, Aboelella NS, Buchsbaum DJ, Boyd MR, Keeton AB, Zhou G. PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. Drug Discov Today 2020;25:1521-7. [PMID: 32562844 DOI: 10.1016/j.drudis.2020.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
302 Feng Y, Neale JR, Doll MA, Hein DW. Chemoprevention of arylamine-induced colorectal aberrant crypts. Exp Biol Med (Maywood) 2008;233:71-5. [PMID: 18156308 DOI: 10.3181/0707-RM-180] [Reference Citation Analysis]
303 Gurpinar E, Grizzle WE, Piazza GA. COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs. Front Oncol. 2013;3:181. [PMID: 23875171 DOI: 10.3389/fonc.2013.00181] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
304 . Perhaps not everyone knows that…. Annals of Oncology 1993;4:800-1. [DOI: 10.1093/oxfordjournals.annonc.a058382] [Reference Citation Analysis]
305 Lee YJ, Lee HR, Nam CM, Hwang UK, Jee SH. White blood cell count and the risk of colon cancer. Yonsei Med J 2006;47:646-56. [PMID: 17066508 DOI: 10.3349/ymj.2006.47.5.646] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]